127 related articles for article (PubMed ID: 8758904)
1. Rb and p16INK4a expression in resected non-small cell lung tumors.
Kratzke RA; Greatens TM; Rubins JB; Maddaus MA; Niewoehner DE; Niehans GA; Geradts J
Cancer Res; 1996 Aug; 56(15):3415-20. PubMed ID: 8758904
[TBL] [Abstract][Full Text] [Related]
2. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers.
Geradts J; Fong KM; Zimmerman PV; Maynard R; Minna JD
Clin Cancer Res; 1999 Apr; 5(4):791-800. PubMed ID: 10213214
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of p27KIP1 expression in resected non-small cell lung cancers: analysis in combination with expressions of p16INK4A, pRB, and p53.
Hirabayashi H; Ohta M; Tanaka H; Sakaguchi M; Fujii Y; Miyoshi S; Matsuda H
J Surg Oncol; 2002 Dec; 81(4):177-84; discussion 184. PubMed ID: 12451621
[TBL] [Abstract][Full Text] [Related]
4. Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity.
Kinoshita I; Dosaka-Akita H; Mishina T; Akie K; Nishi M; Hiroumi H; Hommura F; Kawakami Y
Cancer Res; 1996 Dec; 56(24):5557-62. PubMed ID: 8971152
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of p16INK4A inactivation in non small-cell lung cancers.
Gazzeri S; Gouyer V; Vour'ch C; Brambilla C; Brambilla E
Oncogene; 1998 Jan; 16(4):497-504. PubMed ID: 9484839
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma.
Burke L; Flieder DB; Guinee DG; Brambilla E; Freedman AN; Bennett WP; Jones RT; Borkowski A; Caporaso NA; Fleming M; Trastek V; Pairolero P; Tazelaar H; Midthun D; Jett JR; Liotta LA; Travis WD; Harris CC
Clin Cancer Res; 2005 Jan; 11(1):232-41. PubMed ID: 15671551
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression.
Geradts J; Kratzke RA; Niehans GA; Lincoln CE
Cancer Res; 1995 Dec; 55(24):6006-11. PubMed ID: 8521382
[TBL] [Abstract][Full Text] [Related]
9. Alterations of expression of Rb, p16(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance.
Brambilla E; Moro D; Gazzeri S; Brambilla C
J Pathol; 1999 Aug; 188(4):351-60. PubMed ID: 10440744
[TBL] [Abstract][Full Text] [Related]
10. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines.
Shapiro GI; Edwards CD; Kobzik L; Godleski J; Richards W; Sugarbaker DJ; Rollins BJ
Cancer Res; 1995 Feb; 55(3):505-9. PubMed ID: 7834618
[TBL] [Abstract][Full Text] [Related]
11. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
[TBL] [Abstract][Full Text] [Related]
12. Aberrant p16 expression is correlated with hemizygous deletions at the 9p21-22 chromosome region in non-small cell lung carcinomas.
Spanakis NE; Gorgoulis V; Mariatos G; Zacharatos P; Kotsinas A; Garinis G; Trigidou R; Karameris A; Tsimara-Papastamatiou H; Kouloukousa M; Manolis EN; Kittas C
Anticancer Res; 1999; 19(3A):1893-9. PubMed ID: 10470133
[TBL] [Abstract][Full Text] [Related]
13. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.
Vonlanthen S; Heighway J; Tschan MP; Borner MM; Altermatt HJ; Kappeler A; Tobler A; Fey MF; Thatcher N; Yarbrough WG; Betticher DC
Oncogene; 1998 Nov; 17(21):2779-85. PubMed ID: 9840942
[TBL] [Abstract][Full Text] [Related]
14. RB growth control evasion in lung cancer.
Caputi M; Esposito V; Groger AM; De Luca A; Pacilio C; Dekan G; Giordano GG; Baldi F; Wolner E; Giordano A
Anticancer Res; 1998; 18(4A):2371-4. PubMed ID: 9703881
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers.
Nishio M; Koshikawa T; Yatabe Y; Kuroishi T; Suyama M; Nagatake M; Sugiura T; Ariyoshi Y; Mitsudomi T; Takahashi T
Clin Cancer Res; 1997 Jul; 3(7):1051-8. PubMed ID: 9815783
[TBL] [Abstract][Full Text] [Related]
16. [The expression of P16 and Rb proteins in 106 cases of lung cancer].
Qin J; Chen G; Wang X
Zhonghua Jie He He Hu Xi Za Zhi; 2000 Oct; 23(10):588-90. PubMed ID: 11372380
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of p16INK4A expression in lung adenocarcinoma.
Volm M; Koomägi R; Mattern J
Anticancer Res; 1998; 18(4A):2309-12. PubMed ID: 9703871
[TBL] [Abstract][Full Text] [Related]
18. Expression of p16 and lack of pRB in primary small cell lung cancer.
Yuan J; Knorr J; Altmannsberger M; Goeckenjan G; Ahr A; Scharl A; Strebhardt K
J Pathol; 1999 Nov; 189(3):358-62. PubMed ID: 10547597
[TBL] [Abstract][Full Text] [Related]
19. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB.
Otterson GA; Kratzke RA; Coxon A; Kim YW; Kaye FJ
Oncogene; 1994 Nov; 9(11):3375-8. PubMed ID: 7936665
[TBL] [Abstract][Full Text] [Related]
20. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
